In breast cancer, an anti-CXCL13 antibody suppressed tumor growth by inhibiting the TGF-β1, IL-1, TNF, cyclin D1, and CXCR5/Erk pathways [81,86] and repressed tumor metastasis by inhibiting RANKL production [117]. Here, CCND1 is linked to breast carcinoma.